Clinical Trials /

Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma

NCT01599559

Description:

Primary mediastinal large B cell lymphoma is treated with a combination of chemotherapy and the monoclonal antibody rituximab (chemoimmunotherapy). Following chemoimmunotherapy patients receive radiation therapy if they have residues which may be active tumour. However at the end of chemoimmunotherapy the majority of patients show tissue scarring that is not necessarily active tumor. In recent years, PET/CT has proved to be a good tool to accurately identify active tumor from scar tissue in patients treated for mediastinal lymphoma.The purpose of this trial is to test whether radiation therapy is really necessary in patients where PET/CT has shown that the tumor is no longer active. Therefore we will compare radiation treatment with careful observation. Patients that at the end of conventional treatment of chemoimmunotherapy have a negative PET/CT (i.e., without residues suspected to contain active tumor), will randomly assigned to two different treatment groups: one treatment group will receive the radiation treatment, and the other treatment group will receive careful observation. The trial is planned according to a non-inferiority design aimed at demonstrating that progression free survival after the experimental treatment (observation) is not worse than after the standard comparator (mediastinal irradiation.Participation in this study could spare patients with complete remission at the end of chemo immunotherapy (PET/CT negative) radiation therapy that may be unnecessary.

Related Conditions:
  • Diffuse Large B-Cell Lymphoma
  • Mediastinal Large B-Cell Lymphoma
Recruiting Status:

Active, not recruiting

Phase:

N/A

URL:

https://clinicaltrials.gov/show/NCT01599559

Trial Eligibility

Document

Title

  • Brief Title: Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma
  • Official Title: IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)

Clinical Trial IDs

  • ORG STUDY ID: IELSG37
  • NCT ID: NCT01599559

Conditions

  • Primary Mediastinal B-cell Lymphoma

Purpose

Primary mediastinal large B cell lymphoma is treated with a combination of chemotherapy and the monoclonal antibody rituximab (chemoimmunotherapy). Following chemoimmunotherapy patients receive radiation therapy if they have residues which may be active tumour. However at the end of chemoimmunotherapy the majority of patients show tissue scarring that is not necessarily active tumor. In recent years, PET/CT has proved to be a good tool to accurately identify active tumor from scar tissue in patients treated for mediastinal lymphoma.The purpose of this trial is to test whether radiation therapy is really necessary in patients where PET/CT has shown that the tumor is no longer active. Therefore we will compare radiation treatment with careful observation. Patients that at the end of conventional treatment of chemoimmunotherapy have a negative PET/CT (i.e., without residues suspected to contain active tumor), will randomly assigned to two different treatment groups: one treatment group will receive the radiation treatment, and the other treatment group will receive careful observation. The trial is planned according to a non-inferiority design aimed at demonstrating that progression free survival after the experimental treatment (observation) is not worse than after the standard comparator (mediastinal irradiation.Participation in this study could spare patients with complete remission at the end of chemo immunotherapy (PET/CT negative) radiation therapy that may be unnecessary.

Trial Arms

NameTypeDescriptionInterventions
observationExperimentalFollow up visits are scheduled from randomization. Patients will be seen at 3-months intervals for 24 months, then every 6 months until 5 years from randomization.
    mediastinal irradiationActive ComparatorRadiotherapy will be delivered in this phase III protocol, as alternative to observation, as consolidation treatment in patients achieving a CR status (PET/CT scan negative) at the end of R-chemotherapy, with a total dose of 30 Gy.

      Eligibility Criteria

              Inclusion Criteria:

          -  Previously untreated primary mediastinal diffuse large B-cell lymphoma, CD20 positive.

          -  Patients must have histological confirmation of the diagnosis (it is recommended that
             the immunohistochemical panel includes: CD45, CD20, CD30, CD15, CD10, BCL6, BCL2,
             MUM-1), and in addition have a dominant mass within the anterior mediastinum.

          -  No evidence of extranodal disease outside the chest including spleen and bone marrow.

          -  Age at least 18 years.

          -  Fit to receive chemotherapy and radiotherapy with curative intent.

          -  Patients will be eligible if the treatment phase consisting in a Rituximab combined
             with any anthracycline-containing chemotherapy regimen without consolidation with
             autologous stem cell support (e.g., 6 cycles of CHOP14-21, DA-EPOCH, Mega-CHOP or 12
             weeks of VACOP-B or MACOP-B).

          -  At least 6 courses of Rituximab should be administered

          -  Able and willing to give informed consent, and to undergo staging including PET
             scanning

          -  Willingness to comply with an appropriate contraceptive method in women of
             childbearing potential or men.

          -  Histological diagnostic material available for review.

        Exclusion Criteria:

          -  History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the
             skin or carcinoma in situ of the cervix within the last 5 years.

          -  Evidence of clinically significant cardiac disease at diagnosis, as defined by history
             of symptomatic ventricular arrhythmias, congestive heart failure or myocardial
             infarction within 12 months before study entry. Cardiac impairment due to local
             extension of lymphoma will not be an exclusion criterion in the absence of other
             cardiac disease.

          -  Known HIV-positive serology.

          -  Pregnant or lactating women.

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule.
      Maximum Eligible Age:N/A
      Minimum Eligible Age:18 Years
      Eligible Gender:All
      Healthy Volunteers:No

      Primary Outcome Measures

      Measure:Progression free survival (PFS)
      Time Frame:2 years from the randomization
      Safety Issue:
      Description:The primary outcome endpoint will be Progression Free Survival (PFS) in patients PET-negative after R-chemotherapy. Failure events for PFS are progression (defined as an increase in size of existing masses or the development of new sites of disease using the same radiological investigations CT or PET/CT and/or MRI - as for the pre-chemotherapy assessment) or death from any cause.

      Secondary Outcome Measures

      Measure:Overall survival (OS)
      Time Frame:5 years from registration
      Safety Issue:
      Description:

      Details

      Phase:N/A
      Primary Purpose:Interventional
      Overall Status:Active, not recruiting
      Lead Sponsor:International Extranodal Lymphoma Study Group (IELSG)

      Trial Keywords

      • previously
      • untreated

      Last Updated

      June 7, 2021